AstraZeneca has reaffirmed its 2011 earnings guidance and financial forecasts for the 2010-2014 period after confidential information was mistakenly sent to brokers. The Anglo-Swedish drugmaker noted that "during a routine consensus collection process, confidential company information was inadvertently embedded in a spreadsheet template sent to the sell-side analyst community". That information is out of date "and does not represent the company’s view of expected financial performance for the full year 2011 or for future periods".
